SOURCE: BioCentury Publications, Inc.

BioCentury Publications, Inc.

September 23, 2014 09:00 ET

BioCentury to Showcase 48 Leading Biopharma Companies at the 21st Annual NewsMakers in the Biotech Industry in New York

REDWOOD CITY, CA and NEW YORK, NY--(Marketwired - Sep 23, 2014) - BioCentury will convene the 21st Annual NewsMakers in the Biotech Industry investor conference in New York City this Friday, September 26, at 8 a.m. at the Millennium Broadway Hotel & Conference Center.

The event showcases 48 publicly traded biopharma companies independently selected on the basis of key clinical, regulatory and commercial milestones that will drive valuations going into 2015. More than 600 life science investment professionals and pharmaceutical business development and licensing executives have pre-registered for the event.

Online registration has closed, but on-site registration is available at the Millennium Broadway, 145 West 44th Street, starting at 7:15 a.m. on September 26.

The 2014 NewsMakers Presenting Companies

The presenting companies represent an independently selected mix of biotechs with near-term commercial, regulatory and clinical milestones. They were screened using BioCentury's industry analysis and BCIQ online business intelligence platform. The resulting Class of 2014 represents a group of investor validated companies with ample later-stage milestones and unpartnered assets. Investors have poured more than $4.7 billion into the Class of 2014 since the beginning of 2013, including over $2.3 billion this year. This year's class offers a unique window into some of the newly minted IPOs, with 24 of the presenters jumping through the window since the start of 2013; 18 of them priced this year.

The NewsMakers companies collectively have more than 35 products approved or on the market, and are conducting more than 240 clinical trials, including 30 Phase III studies and more than 140 Phase II trials across key disease areas including cancer, infectious diseases, inflammation, cardiovascular and autoimmune disorders.

The NewsMakers assets include more than 170 unpartnered products that should be of interest to pharma business development and licensing professionals, with more than 80 of them in the clinic.

"Biotech is in the midst of a record five-year run, outpacing the key equity indices, including the Dow Jones Industrials and the S&P 500," noted BioCentury Publisher Eric Pierce. "Members of the NewsMakers Class of 2014 have played a significant role in drawing investors into the biotech space. We're pleased to have the opportunity to showcase them and their near-term milestones to the investment community at NewsMakers."

NewsMakers 2014 Class of Presenting Companies (NASDAQ listed unless otherwise noted)

Actinium Pharmaceuticals Inc. (NYSE-M:ATNM)
Acucela Inc. (Tokyo:4589)
Agile Therapeutics Inc. (AGRX)
Alnylam Pharmaceuticals Inc. (ALNY)
Arena Pharmaceuticals Inc. (ARNA)
Argos Therapeutics Inc. (ARGS)
Arrowhead Research Corp. (ARWR)
Avalanche Biotechnologies Inc. (AAVL)
BioSpecifics Technologies Corp. (BSTC)
Celator Pharmaceuticals Inc. (CPXX)
Celladon Corp. (CLDN)
Cempra Inc. (CEMP)
Cerulean Pharma Inc. (CERU)
ContraFect Corp. (CFRXU)
Cyclacel Pharmaceuticals Inc. (CYCC)
CytRx Corp. (CYTR)
Eagle Pharmaceuticals Inc. (EGRX)
Epirus Biopharmaceuticals Inc. (EPRS)
Esperion Therapeutics Inc. (ESPR)
Genocea Biosciences Inc. (GNCA)
GlobeImmune Inc. (GBIM)
GlycoMimetics Inc. (GLYC)
Horizon Pharma Inc. (HZNP)
Incyte Corp. (INCY)
Inovio Pharmaceuticals Inc. (INO)
Kite Pharma Inc. (KITE)
MEI Pharma Inc. (MEIP)
Mirati Therapeutics Inc. (MRTX)
Momenta Pharmaceuticals Inc. (MNTA)
NeoStem Inc. (NBS)
Ocular Therapeutix Inc. (OCUL)
OncoMed Pharmaceuticals Inc. (OMED)
Orexo AB (SSE:ORX; OTCQX:ORXOY)
Pain Therapeutics Inc. (PTIE)
Pfenex Inc. (NYSE-M:PFNX)
Prosensa Holding N.V. (RNA)
Radius Health Inc. (RDUS)
Relypsa Inc. (RLYP)
Repros Therapeutics Inc. (RPRX)
SciClone Pharmaceuticals Inc. (SCLN)
Spectrum Pharmaceuticals Inc. (SPPI)
Synthetic Biologics Inc. (NYSE-M:SYN)
Tetraphase Pharmaceuticals Inc. (TTPH)
Tonix Pharmaceuticals Holding Corp. (TNXP)
uniQure N.V. (QURE)
ZS Pharma Inc. (ZSPH)

See the Presenting Company schedule and additional program highlights at http://www.biocentury.com/Data/NewsCenter2/Conferences/ConferencesFiles/NM14schedule.pdf.

Sponsors Demonstrate Long-Term Commitment to Industry

The NewsMakers 2014 sponsors are anchored by Gold Sponsors L.E.K. Consulting; WBB Securities; and William Blair. They are joined by Silver Sponsors AstraZeneca; Johnson & Johnson; Laidlaw & Co.; Oxford Finance; and Tiberend Strategic Advisors, along with Networking Lunch Sponsor Panasonic Healthcare.

Future BioCentury Conferences

NewsMakers is one of two premier investor conferences organized annually by BioCentury in New York. The next conference, the 22nd Future Leaders in the Biotech Industry, will take place in New York City on March 20, 2015. Future Leaders connects leading portfolio managers, bankers, analysts and business development professionals with investor-validated, milestone-rich private and public innovator companies in key therapeutic areas.

BioCentury also will be convening its first BioCentury China Healthcare Summit: The Bridge to Innovation in Shanghai on November 12-13, 2014. The BioCentury China Healthcare Summit, co-organized with BayHelix, is a strategic, VIP event designed to bring together thought leaders and decision makers from Chinese and multinational companies to examine the necessary steps to creating a modern healthcare ecosystem in China that is built on a foundation of scientific, business and policy innovation.

For more information, and to register for the BioCentury China Healthcare Summit, visit http://www.biocentury.com/conferences/chinasummit/dates.

BioCentury also is preparing the 16th annual BioEquity Europe, which will take place in Vienna on May 19-20, 2015. BioEquity Europe is the premier event for financial dealmakers looking for investor-validated European life science companies positioning themselves to attract capital, and for business development and licensing professionals from pharmaceutical companies to assess top partnering and licensing prospects.

About BioCentury

Since 1993, BioCentury Publications, Inc. has provided essential biopharma industry intelligence to a global audience of biotech and pharmaceutical executives, investors, regulators and public policy makers, and the scientific community. This audience has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, data products and collaborative industry conferences in the U.S., Europe and Asia.

BioCentury's titles include the flagship weekly journal BioCentury®; its SciBX™ translational science partnership with Nature Publishing Group; and its BioCentury Extra mobile daily newspaper. These timely journals are backed by BCIQ™, an online business intelligence resource. BioCentury also produces its BioCentury This Week healthcare public affairs television program in partnership with the Gannett-owned WUSA CBS affiliate in Washington, D.C. The program is aired in the nation's capital every Sunday, on Public Broadcasting System member stations in selected markets, and is always available globally online at www.biocenturytv.com.

For more information, visit www.biocentury.com and www.biocenturytv.com.